Dr. Alice Gottlieb, Clinical Professor, Mount Sinai Union Square Dermatology, Kimberly and Eric J. Waldman Department of Dermatology at The Icahn School of Medicine at Mount Sinai, is an internationally recognized expert in the field of psoriasis and psoriatic arthritis and is triple board-certified in dermatology, rheumatology, and internal medicine. Over the course of her illustrious career, Dr. Gottlieb has held many leadership positions, published over 500 groundbreaking peer-reviewed articles, and presented her original research at more than 370 dermatology and rheumatology conferences in the U.S. and internationally. She is the recipient of many awards for excellence in teaching and research. Additionally, Dr. Gottlieb’s work has contributed to drug development in psoriasis, psoriatic arthritis, rheumatoid arthritis, hidradenitis suppurativa, vitligo, inflammatory bowel disease, and transplantation. She is the founder and President of the International Dermatology Outcome Measures (IDEOM) group, on the Steering Committee of GRAPPA, the group devoted the research in psoriasis and psoriatic arthritis, and a councilor of the International Psoriasis Council. Dr. Gottlieb currently serves on NPF’s Scientific Advisory Committee and has been supporting NPF for over 30 years.

In addition to his role as Director of the Colton Center for Autoimmunity at NYU Langone, Dr. Scher is the Steve Abramson Associate Professor of Medicine, Associate Director of Research and Translational Medicine for the Division of Rheumatology, and the Director of the Psoriatic Arthritis Center (PAC).

Through the work at the PAC, a clinical and translational hub for the study of psoriatic disease, a team of rheumatologists, dermatologists, immunologists, and computational scientists work together to address the many unmet needs in the field. Dr. Scher’s research interests include the immune and environmental features that enhance risk for transition from psoriasis to psoriatic arthritis (PsA), the mechanisms behind inflammation in psoriatic and rheumatoid disease, and the pharmacomicrobiomics of DMARDs and immunotherapies in human RA and PsA. His work is supported by grants from the NIH/NIAMS, the Rheumatology Research Foundation, National Psoriasis Foundation, and Bloomberg Philanthropies, among others.

Dr. Scher currently chairs NPF’s Scientific Advisory Committee and was one of two principal investigators on NPF’s PsA Diagnostic Test Grant initiative.

The creation of a PsA diagnostic test is the first step on the road to a cure. A diagnostic test will dramatically reduce the guesswork and the long delays in reaching a diagnosis and beginning treatment.

Psoriatic disease is associated with inflammation throughout the body, increasing the risk of high cholesterol, high blood pressure, and diabetes, among other comorbidities. Funded through NPF's Psoriasis Prevention Initiative, the CP3 study is evaluating the use of an innovative care coordination model in lowering cardiovascular risk in patients with psoriatic disease.